Introduction {#sec1-1}
============

Epilepsy and epileptic disorders are distinguished by recurrent and unpredictable seizures ([@ref1]) affecting one percent of people worldwide ([@ref2]). Almost 30--40% of cases seem to be intractable despite various treatments ([@ref3]). Mesial temporal lobe epilepsy (mTLE) is the most common type of epilepsy in the population ([@ref4]) with high economical consequences every year ([@ref5]). Various cellular abnormalities such as loss of pyramidal neurons of CA1 and CA3 regions of the hippocampus, mossy fiber sprouting (MFS), and granule cell layer dispersion ([@ref5]) may be responsible for the pathology. Among these, MFS is the best-known form of axonal plasticity in epilepsy ([@ref6], [@ref7]), which leads to hyperexcitability and increases seizure intensity ([@ref5]). On the other hand, oxidative stress, which results from an imbalance of oxidant and antioxidant factors ([@ref8], [@ref9]), is another phenomenon involved in epileptogenesis ([@ref10]-[@ref13]). A study showed that ROS (Reactive Oxygen Species) plays a role in neuronal toxicity-induced apoptosis and increased seizures ([@ref14]).

An increasing interest is devoted to herbal remedies as a treatment for epilepsy disorders ([@ref15]). Eugenol (4-allyl-2-methoxyphenol), is an aromatic compound found in the essential oils of several plants such as *Rosa spp, Eugenia caryophyllata, Cinnamomum verum, Valeriana officinalis* ([@ref16], [@ref17]), allspice, nutmeg, basil, and bay leaf ([@ref18], [@ref19]). It is increasingly used in medicine ([@ref20], [@ref21]), and because of its ability in modulating neuronal excitability ([@ref22]) may help to cure some diseases. Gorji and Khaleghi Ghadiri in 2001 and 2002 reported that plants containing eugenol can alleviate the symptoms of some neurological disorders like recurrent unilateral and bilateral headaches and epilepsy ([@ref23], [@ref24]). Furthermore, *Laurus nobilis* essential oil containing eugenol has a usage in traditional medicine of Iran as an anticonvulsant agent ([@ref25], [@ref26]). Eugenol has shown an anticonvulsant effect against seizures induced by maximal electroshock and PTZ ([@ref27]), which are both acute in nature without chronic precipitant consequences. Therefore, in this study, the effect of eugenol on acute convulsive behavior as well as consequent oxidative stress and histological changes in the hippocampus of the lithium-pilocarpine rat model of epilepsy were explored.

Materials and Methods {#sec1-2}
=====================

Experimental animals {#sec2-1}
--------------------

Male 2.5 month old Wistar rats weighing 220--250 g were purchased (Razi Institute, Karaj, Iran) and used in this study. All experiments were done in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 23-80, revised 1996) and were approved by the research ethical standards for the care and use of animals in Damghan University. Rats were kept 5 per cage, under normal 12- 12 hr light- dark cycle, with lights on at 07:00 am, and food and water *ad libitum*.

Animal groups {#sec2-2}
-------------

Male rats were divided into 4 groups. 1. The Control group (Ctrl; n=12) received lithium chloride (3 meq/kg, intraperitonealy (IP)) to become comparable with the pilocarpine group. 2. Pilocarpine group (PL; n=14) received pilocarpine (30 mg/kg, IP ([@ref28])). 3. Eugenol-Pilocarpine group (PL-EUG; n=17) received eugenol (100 mg/kg, IP ([@ref22])) for 7 days ([@ref29]) followed by lithium-pilocarpine on the 3^rd^ day. 4. Eugenol group (EUG; n=16) received eugenol (100 mg/kg, IP) for 7 days. All groups received lithium and atropine at the time mentioned in the next section for the pilocarpine group.

The lithium-pilocarpine model of epilepsy {#sec2-3}
-----------------------------------------

Lithium chloride (3 meq/kg, IP) was injected 20 hr before pilocarpine injection (30 mg/kg, IP), which was given repeatedly (limited to three injections per rat) every 30 min until the rats developed seizures ([@ref30]). Atropine sulfate was (1 mg/kg, IP) injected 5 min prior to pilocarpine to reduce peripheral cholinergic effects ([@ref31]). Then, diazepam was administered around 60 min after the onset of the status epilepticus to improve survival after the convulsion in PL and PL-EUG groups and in control and EUG groups for comparison, all in doses of 10, followed by 2.5 mg/kg, IP half an hour later. Seizures were scored in each rat upon modified Racine's scale based on behavioral assessment of only convulsive (motor) seizures: stage 1, facial automatisms; stage 2, facial and head clonus; stage 3, forelimb clonus; stage 4, rearing; stage 5, rearing plus loss of balance and falling that was accompanied by generalized clonic (GC) convulsions ([@ref30]). During one hour of behavioral observation, seizure stages (modified from Racine scales ([@ref32])), seizure latency (the time to GC convulsions; GC Latency), and GC duration were evaluated. Four weeks later, following the latent period, all hippocampal tissues were collected for biochemical and fixed using paraformaldehyde for histological evaluations.

Assessment of oxidative stress markers {#sec2-4}
--------------------------------------

After sacrificing animals and extraction of the hippocampus on day 28, oxidative markers were measured using a biochemical method. The concentration of malondialdehyde (MDA), as a marker of lipid peroxidation, was calculated by measuring thiobarbituric acid reactive substances (TBARS). The contents of superoxide dismutase (SOD) and glutathione peroxidase (GPx), as antioxidant enzymes, were measured to determine oxidative stress levels. The concentrations of MDA, SOD, and GPx were expressed as nmol/mg protein, U/mg protein, and ΔA/min/mg protein, respectively.

The protein content was measured by the Lowry method, using bovine serum albumin as the standard.

Histological studies {#sec2-5}
--------------------

For Nissl staining, animals (n=5 for each group) were deeply anesthetized, on day 28, with ketamine (90%) and xylazine (10%) and perfused through the ascending aorta with 50 ml of normal saline followed by formalin (10%). Following perfusion, the brains were removed from the skulls and immersed in formalin for 24--48 hr. Then, sections were cut with a microtome with a thickness of 10 μm in a range between −3.72 and −4.44 mm from the bregma. The sections were Nisslstained with cresyl violet (Sigma). The cells of CA1, CA3, and dentate gyrus of the hippocampus were counted in the six consecutive sections using a grid (250 µm length) - installed light microscopy at a 40x magnification. The average of six sections for every region was taken as the final value for that region.

Timm stainingroup were deeply anesthetized with ketamine (90%) and xylazine (10%) and perfused through the ascending aorta with 50 ml of normal saline followed by 100 ml of sulfide solution (1.2% Na~2~S and 1.0% NaH~2~PO~4~) until the extremities turned blue/gray and by 100 ml of 4% paraformal-dehyde in 0.1 M phosphate buffer (pH 7.4). Following perfusion, the hippocampi were removed from the skull and were immersed in formalin for 24--48 hr. Then, the sections were cut with a microtome at a thickness of 10 μm. The slices were washed in 100%, followed by 95% alcohol and deionized water. For labeling the zinc-containing axons of the granule cells, the sections were stained with Timm stain solution under continuous agitation in the dark at room temperature for 45 min, and then at 60 °C for 20 min. Slides were washed with deionized water and sealed with a coverslip.

The Timm solution contains 120 ml of 50% gum Arabic, 20 ml of 2 M sodium citrate buffer (pH 3.7), 60 ml of 5.6% hydroquinone, and one ml of 17% silver nitrate. Timm-stained slices were scored according to 0--3 rating scale of Tauck & Nadler ([@ref33]), with a score of zero indicating little or no Timm staining in the granule cell layer; 1 indicated mild, patchy staining in the granule cell layer; 2 indicated moderate continuous staining through the granule cell layer with discontinuous, punctate staining in the inner molecular layer; and 3 indicated a continuous band of intense staining in the inner molecular layer. Finally, the Timm index was calculated as average of four sections per group. In addition to Timm index, we employed the mean coloring duration of hippocampal tissues as a new variable to show the extent of MFS.

Drugs {#sec2-6}
-----

Pilocarpine hydrochloride (cat, P6503; Cholino-mimetic) and lithium chloride (cat, 203637) from Sigma-Aldrich and diazepam and atropine sulfate (anti-cholinergic), from a local market in IRAN, were used in this research.

Statistical analysis {#sec2-7}
--------------------

For statistical comparisons between groups, significance was determined using one-way ANOVA followed by Tukey's *post hoc* test and Kruskal-Wallis test for non-parametric data. For statistical comparison between two independent groups, significance was evaluated by unpaired two-tailed Student's t-test. All statistical analyses were performed using SPSS software v.16. The level of significance was set at *P*\<0.05. The data were expressed as means ± SEM.

Results {#sec1-3}
=======

Eugenol reduced pilocarpine-induced behavioral seizures {#sec2-8}
-------------------------------------------------------

Eugenol increased GC latency in PL-EUG group (unpaired two-tailed Student's t-test, *P*\<0.05, n=7) compared to the PL group and also decreased seizure stages in the PL-EUG group compared to the PL group. The data demonstrated a reduction in GC duration of the PL-EUG group (unpaired two-tailed Student's t-test, *P*\<0.05, n=7) compared to the PL group. Seizures caused 61.11% mortality in the PL group, while eugenol decreased mortality in PL-EUG by 21.83% (39.28% in this group). There was only 5.88% mortality in the EUG group ([Figure 1](#F1){ref-type="fig"}).

![Effect of eugenol on behavioral convulsions. Eugenol increased latency to the clonic convulsions compared to pilocarpine (A). Seizure stages (B) and GC duration (C) decreased due to eugenol. Pilocarpine increased mortality, and eugenol partially reversed the effect (D). † P\<0.05, PL; Pilocarpine, EUG; Eugenol, GC; Generalized Clonic Convulsions](IJBMS-20-745-g001){#F1}

Eugenol could reverse epilepsy-induced oxidative stress {#sec2-9}
-------------------------------------------------------

Previous studies implied the antioxidant effect of eugenol ([@ref34], [@ref35]). To evaluate the effect of pilocarpine on oxidative stress and investigate therapeutic effects of eugenol, we assessed oxidative stress markers.

One way ANOVA showed a different MDA level between groups \[F (3, 18) = 41. 799, *P*= 0. 0005\]. There was an increase in MDA levels of PL (Tukey, *P*\<0.05, n=6), PL-EUG (Tukey, *P*\<0.01, n=6) and EUG (Tukey, *P*\<0.001, n=6) groups compared to control. There were no differences in MDA levels between PL and PL-EUG groups ([Figure 2A](#F2){ref-type="fig"}).

![Eugenol activated the oxidative processes in the hippocampus. MDA increase was due to pilocarpine epilepsy and/or eugenol (A), while GPx increase was seen only in eugenol treated animals (B). SOD increase was shown due to eugenol in naïve animals (C).\
\* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, \* compared to Ctrl, Ctrl; Control, PL; Pilocarpine, EUG; Eugenol](IJBMS-20-745-g002){#F2}

Comparing different groups using one-way analysis of variance showed a significant difference in the GPx level \[F (3, 18) = 3.958, *P*= 0. 02\]. GPx level increased in the EUG group (Tukey, *P*\<0.05, n=6) compared to the control group. There was no difference in GPx level between PL and PL-EUG with the control group ([Figure 2B](#F2){ref-type="fig"}).

One-way analysis of variance statistical comparison showed a different SOD content between groups \[F (3, 18) = 5.865, *P*=0.006\]. SOD content increased in the EUG group (Tukey, *P*\<0.01, n=6) compared to controls. However, there was no difference in SOD levels between PL and PL-EUG group ([Figure 2C](#F2){ref-type="fig"}).

Eugenol preserved neuronal population and prevented axonal sprouting {#sec2-10}
--------------------------------------------------------------------

To evaluate surviving cell numbers after pilocarpine -induced seizures and the effect of eugenol, hippo-campal sections were Nissl stained after 28 days and neurons of CA1, CA3, and DG regions of the hippocampus were counted. One-way ANOVA comparison revealed a significant difference between different groups \[F (3, 16)=15.703, *P*=0.0005\]. Nissl staining showed that there was a reduction in total cell count in PL (Tukey, *P*\<0.001, n=5) and EUG groups (Tukey, *P*\<0.001, n=5) compared to the control group, while the neuronal count showed a reverse trend in the PL-EUG group (Tukey, *P*\<0.01, n=5) compared to the PL group ([Figure 3A](#F3){ref-type="fig"}).

Surviving neurons in DG region decreased due to pilocarpine (Tukey, *P*\<0.01, n=5) and were compensated in the PL-EUG group (Tukey, *P*\<0.05, n=5), while decreasing (Tukey, *P*\<0.01, n=5) in the EUG only group ([Figure 3B](#F3){ref-type="fig"}). Similarly, CA3 and CA1 (Tukey, *P*\<0.05, n=5) cell count decreased in the PL group compared to control (Figures [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}) and were compensated due to EUG treatment. Moreover, Nissl staining represented cell dispersion in CA1 and CA3 regions of the hippocampus in the the PL group ([Figure 4](#F4){ref-type="fig"}).

![Eugenol prevented the hippocampal neuronal loss. While pilocarpine-induced neuronal loss in the total hippocampus, eugenol prevented that effect (A). Pilocarpine and eugenol increased and prevented, respectively, neuronal loss in DG (B), CA3 (C) and CA1 (D) Eugenol alone decreased neuronal survival in the total hippocampus, DG, and CA3\
\* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, †*P*\<0.05, \* compared to Ctrl and † compared to PL, Ctrl; Control, PL; Pilocarpine, EUG; Eugenol](IJBMS-20-745-g003){#F3}

![Photomicrographs showing Nissl staining of the hippocampal dentate and CA regions of epileptic animals. Control sections showed normal stained DG, CA3, and CA1 neurons (well-arranged and distributed neurons). PL sections reveal reduced and dispersed neuronal numbers, while eugenol restored the number, but not the dispersion except in DG. eugenol itself decreased neuronal survival and increased dispersion in DG, CA3, and CA1. Ctrl; Control, PL; Pilocarpine, EUG; Eugenol](IJBMS-20-745-g004){#F4}

To represent axonal sprouting, hippocampal sec-tions were Timm-stained and mossy fiber's staining was scored according to Tauck & Nadler scale ([@ref33]). Kruskal-Wallis comparison revealed a significant difference of the Timm index between different groups (*P*=0.006). Pairwise multiple comparisons of the groups showed a remarkable MSF in the PL group (*P*\<0.001, n=4; [Figure 5](#F5){ref-type="fig"}). Although MFS was also demonstrated in PL-EUG (*P*\<0.01, n=4) and EUG groups (*P*\<0.05, n=4) compared to control, there was a reduction in PL-EUG (*P*\<0.01, n=4) compared to the PL group ([Figure 5A](#F5){ref-type="fig"}).

![Eugenol prevented hippocampal mossy fiber sprouting in the dentate gyrus. The mean Timm index was increased due to epilepsy (PL) and was prevented after eugenol administration, while eugenol alone partially increased the index (A). Coloring time was reduced in epileptic animals while it took longer due to eugenol IP injections (B)\
\*\* *P*\<0.01, \*\*\* *P*\<0.001, †† *P*\<0.01, ††† *P*\<0.001, \* compared to Ctrl and † compared to PL, Ctrl; Control, PL; Pilocarpine, EUG; Eugenol](IJBMS-20-745-g005){#F5}

As Timm index showed a higher grade due to epilepsy, we demonstrated a different capacity of coloring time between groups, therefore coloring time as a new variable for MFS intensity was employed. Mean coloring time of hippocampal sections using one-way ANOVA revealed different durations \[F (3, 12) = 23.018, *P*=0.0005\], with the PL group having the lowest time (colored faster) (Tukey, *P*\<0.01, n=4) while the eugenol increased the mean coloring time in PL-EUG (Tukey, *P*\<0.001, n=4) and EUG (Tukey, *P*\<0.001, n=4) groups compared to the PL group (colored slowly) ([Figure 5B](#F5){ref-type="fig"}).

Discussion {#sec1-4}
==========

In this study, the effect of eugenol on convulsive behavior, oxidative stress, and consequent histological changes in a lithium-pilocarpine model of epilepsy were explored. We demonstrated that eugenol reduced seizure severity and animal mortality. In addition, eugenol treatment prevented the epilepsy induced reduction of neuronal numbers and MFS in all hippocampal sub-regions: DG and CAs, however, eugenol alone decreased neuronal survival. Furthermore, pilocarpine increased the MDA content, while eugenol increased not only MDA but also other markers in the naïve animals.

Eugenol revealed an increase of GC latency (the time from injection to the onset of tonic-clonic convulsions) and a decrease in GC duration. Moreover, animals developed lower seizure stages due to eugenol. These results are in agreement with previously published studies in the acute preparations ([@ref22], [@ref36], [@ref37]). In accordance, previous studies suggested that eugenol can modulate neuronal excitability and can affect the firing of action potentials ([@ref22]) through modulation of ionic channels involved in the seizure activity of pilocarpine-induced epilepsy; such as voltage gated sodium ([@ref38]) and calcium channels ([@ref39]-[@ref42]). Therefore, it is assumed that eugenol has probably modulated these channels ([@ref22], [@ref43]) and hence decreased neuronal excitability. On the other hand, a study showed that eugenol potentiates the response of GABA in low concentrations (probably by increasing the affinity of GABA for the receptors) ([@ref44]). Thus, anticonvulsant effects of eugenol may be due to its ability to decrease neuronal excitability and potentiating the inhibitory responses. This eugenol effect in modulating seizure intensity may be responsible for the decreased mortality in eugenol treated animals.

Some studies mentioned antioxidant effects of eugenol ([@ref20], [@ref21]) which was confirmed in our study with the increase of GPx and SOD antioxidant markers. In contrast, there was an elevation of the MDA lipid peroxidation index level due to eugenol in healthy and epileptic brains. Although the MDA increase in epileptic animals may indicate the behavioral and structural consequences of convulsions, its increase following eugenol treatment was unpredictable. There are reports concerning dose-related effects of eugenol from neuroprotection to neurodevastating, with low to high doses, respectively ([@ref45], [@ref46]), and the dose used in this study was assigned as high in some studies ([@ref45]). It appears that in such a dose, eugenol facilitates the conversion of glucose to glycogen and hence the depletion of NADPH as the precursor of glutathione ([@ref47]) which may indicate the increase of oxidative stress. On the other hand, eugenol increased SOD and GPx activity, but due to the depletion, they may not be able to convert the oxidative molecules to water. In contrast, combined pilocarpine and eugenol treatment increased GPx, which, along with the lower MDA levels demonstrated, may indicate the pilocarpine enhancing effect of the glucose production and hence conversion to NADPH shown in a study on status epilepticus induced long-term inhibition of glycogen phosphorylase ([@ref48]). Therefore, we assumed that combined treatment may prevent the eugenol induced MDA buildup and the consequent decrease in oxidative outcomes.

Neuronal survival was demonstrated to be decreased after pilocarpine-induced epilepsy while treating with eugenol reversed the detrimental effect and increased the survival which indicates the neuroprotective effect of eugenol. In addition to its effects on GPx levels shown in this study and the consequent prevention of MDA buildup, eugenol may inhibit the intracellular calcium increase, cytochrome-c release, and caspase3 activation and also decrease caspase3 protein expression ([@ref34]). Conversely, eugenol alone decreased neuronal population as strong as pilocarpine-induced epilepsy which may be attributable to MDA buildup and the resulting lipid peroxidation induced oxidative stress. Studies suggest that the eugenol induced ROS increase may lead to apoptosis, especially in high doses ([@ref49]) and this cytotoxic effect is due to Quinone Methide production ([@ref50]).

Moreover, Nissl staining revealed neuronal dispersion in CA1, CA3, and DG of the hippocampus due to pilocarpine and/or eugenol. This is previously explained by Reelin protein loss that is necessary for neural migration and lamination ([@ref51]-[@ref54]). The pilocarpine-induced glutamate release and prolonged BDNF gene expression promotion lead to Reelin loss and subsequent abnormal migration of hippocampal neurons ([@ref55], [@ref56]). Eugenol is also shown to increase BDNF gene expression ([@ref57]), similar to seizure-induced BDNF increase ([@ref58]), and therefore may lead to Reelin loss and neuronal dispersion in eugenol treated animals, however, it has shown an ameliorating effect on neuronal dispersion in lower doses through inhibition of mTORC1 expression ([@ref37]).

While epilepsy results in various morphological changes in hippocampus such as MSF ([@ref7]) that leads to increased tissue excitability ([@ref5]), some studies suggest that inhibition of axonal sprouting decreases the excitability ([@ref5]). Timm staining, a method for representing MFS, indicated seizure-induced MFS after pilocarpine treatment. Although MFS was obvious due to pilocarpine and/or eugenol, it was reduced after eugenol application, probably through increasing BDNF expression ([@ref57]) and inhibiting voltage-gated calcium channels ([@ref43]). The assumption of eugenol induced BDNF gene expression may explain the demonstrated MFS in control animals treated with eugenol ([@ref57]).

Conclusion {#sec1-5}
==========

Eugenol decreased pilocarpine-induced seizure intensity as well as mortality. It also increased cell survival in hippocampal sub-regions and prevented MSF in the molecular layer of the dentate gyrus in the epileptic animals. Conversely, eugenol, probably in the administered dose, could not reduce lipid peroxidation marker, MDA, and increased the neuronal loss in the hippocampus. Although eugenol exhibited anticonvulsive and neuroprotective effects at this dose in the combined treatment, it is needed to set a dose response study in future experiments, as it has shown a U-shaped curve in inhibiting stress effects, to clarify the responsible mechanisms. Moreover, measuring glutathione content in such a study will help to test its absence in eugenol neurodegeneration and its probable role in the establishment of new therapies for epilepsy induced structural damage.
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